NRCC
NOTICE OF REGISTRATION CONFIRMATION EMAILED
01/06/2026
Back to search
Official data from USPTO
RENMAB
Did you know this trademark is already registered in United States?
Before investing in name, identity, and promotion, validate collision risk and registration strategy to avoid wasting time and budget.
Active USPTO registrationType: WordOffice: United States
Risk and opportunity diagnosis
Executive reading for naming, filing, and monitoring decisions.
USPTO status
Active USPTO registration
Case type
Application and registration
Recorded events
49
Latest update
01/06/2026
Trademark type
Word
Nice classes
5
Filing date
07/31/2019
Registration date
01/06/2026
Expiration date
-
Complete case details
Structured fields from the responsible authority and the official record.
Status date
01/06/2026
Last transaction
01/06/2026
Responsible office
United States Patent and Trademark Office
Status code
700
Official register
Principal Register
Filing basis
Intent to use, Foreign priority
First use anywhere
06/01/2020
First use in commerce
06/01/2020
Drawing code
4
Owner type
99
Owner location
Daxing District, Beijing, CN
Examiner
CROWLEY, SEAN MICHAEL
Law office
M70
Current location
PUBLICATION AND ISSUE SECTION
Holders and representatives
Holders
BIOCYTOGEN PHARMACEUTICALS (BEIJING) CO.
BIOCYTOGEN PHARMACEUTICALS (BEIJING) CO.
Beijing Biocytogen Co., Ltd.
Representatives
CYNTHIA JOHNSON WALDEN Fish & Richardson P.C.
Technical classification
Nice Classes
Class 5
Vienna Codes
No Vienna codes available.
Goods and services
Class 5
Medical immunoassay reagent derived from experimental animals; medical biological preparations for the treatment of diseasesantibodies and proteins for biopharmaceuticals derived from experimental animals; drugs for treating cancerantibodies and proteins for biopharmaceuticals derived from experimental animals; medicines for human purposesfor the treatment of diseasesantibodies and proteins for biopharmaceuticals derived from experimental animals; biochemical drugs for the treatment of diseasesantibodies and proteins for biopharmaceuticals derived from experimental animals; immunologic stimulants for medical use for the treatment of diseasesantibodies and proteins for biopharmaceuticals derived from experimental animals; bulk drugs for the treatment of diseasesActive Biopharmaceutical Ingredients derived from experimental animals; medical diagnostic preparationantibodies and proteins for biopharmaceuticals derived from experimental animals
Publications
History of USPTO decisions and trademark events.
49 publications found
R.PR
REGISTERED-PRINCIPAL REGISTER
01/06/2026
SUNA
NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED
12/18/2025
CNPR
ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED
12/18/2025
SUPC
STATEMENT OF USE PROCESSING COMPLETE
11/14/2025
IUAF
USE AMENDMENT FILED
11/13/2025
EISU
TEAS STATEMENT OF USE RECEIVED
11/13/2025
DPCC
DIVISIONAL PROCESSING COMPLETE
10/27/2025
AITU
CASE ASSIGNED TO INTENT TO USE PARALEGAL
10/23/2025
EXRA
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
10/02/2025
EX1G
SOU EXTENSION 1 GRANTED
10/01/2025
AITU
CASE ASSIGNED TO INTENT TO USE PARALEGAL
10/01/2025
EEXT
SOU TEAS EXTENSION RECEIVED
05/19/2025
DRRR
DIVISIONAL REQUEST RECEIVED
05/18/2025
EXT1
SOU EXTENSION 1 FILED
05/18/2025
ERTD
TEAS REQUEST TO DIVIDE RECEIVED
05/18/2025
CHAN
APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
05/13/2025
EPPA
TEAS POST PUBLICATION AMENDMENT RECEIVED
05/01/2025
NOAM
NOA E-MAILED - SOU REQUIRED FROM APPLICANT
11/19/2024
TMBN
TTAB RELEASE CASE TO TRADEMARKS
10/21/2024
OP.T
OPPOSITION TERMINATED NO. 999999
10/21/2024
OP.D
OPPOSITION DISMISSED NO. 999999
10/21/2024
OP.I
OPPOSITION INSTITUTED NO. 999999
02/14/2022
ETOF
EXTENSION OF TIME TO OPPOSE RECEIVED
09/15/2021
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
08/17/2021
PUBO
PUBLISHED FOR OPPOSITION
08/17/2021
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
07/28/2021
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
07/09/2021
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
07/09/2021
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
07/09/2021
ERSI
TEAS RESPONSE TO SUSPENSION INQUIRY RECEIVED
07/06/2021
ASGN
AUTOMATIC UPDATE OF ASSIGNMENT OF OWNERSHIP
02/17/2021
GNS2
NOTIFICATION OF INQUIRY AS TO SUSPENSION E-MAILED
01/05/2021
GNSI
INQUIRY TO SUSPENSION E-MAILED
01/05/2021
CNSI
SUSPENSION INQUIRY WRITTEN
01/05/2021
RCCK
SUSPENSION CHECKED - TO ATTORNEY FOR ACTION
12/02/2020
GNS3
NOTIFICATION OF LETTER OF SUSPENSION E-MAILED
05/29/2020
GNSL
LETTER OF SUSPENSION E-MAILED
05/29/2020
CNSL
SUSPENSION LETTER WRITTEN
05/29/2020
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
05/12/2020
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
05/12/2020
ALIE
ASSIGNED TO LIE
05/08/2020
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
05/05/2020
GNRN
NOTIFICATION OF NON-FINAL ACTION E-MAILED
11/05/2019
GNRT
NON-FINAL ACTION E-MAILED
11/05/2019
CNRT
NON-FINAL ACTION WRITTEN
11/05/2019
DOCK
ASSIGNED TO EXAMINER
10/28/2019
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
08/14/2019
NWAP
NEW APPLICATION ENTERED
08/03/2019
Continuous trademark protection
Get notified about every new filing that threatens RENMAB or your mark.
Professional 24-month watch service: we monitor USPTO for you and alert you in time to oppose — before conflicts become losses.